Scientists hunt for clues to predict liver cancer drug response

NCT ID NCT05197504

Completed Knowledge-focused Sponsor: CHA University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This completed study analyzed tumor and blood samples from 166 people with advanced liver cancer who received a combination of atezolizumab and bevacizumab. The goal was to find biomarkers—biological clues—that could predict how well a patient responds to treatment and how long they survive. Researchers used advanced genetic and molecular techniques to better understand the disease and identify potential new treatment targets.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: atezolizumab plus bevacizumab
What this could lead to: If successful, this could help identify which patients are most likely to benefit from this drug combination, leading to more personalized treatment for advanced liver cancer.
What could go wrong: This is an observational biomarker study, not a treatment trial. It may not find clear or useful biomarkers, and results may not change clinical practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATOCELLULAR CARCINOMA

Contacts and locations

Locations

CHA Bundang Medical Center

Seongnam-si, Gyeonggi-do, 13496, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.